SCA
ABBV icon

Sippican Capital Advisors’s AbbVie ABBV Stock Holding History

Sippican Capital Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.26M Sell
12,947
-75
-0.6% -$16.1K 1.99% 10
2026
Q1 		$2.83M Sell
13,022
-437
-3% -$96.9K 1.94% 10
2025
Q4 		$3.08M Sell
13,459
-476
-3% -$108K 1.98% 11
2025
Q3 		$3.23M Sell
13,935
-75
-0.5% -$15.3K 2.13% 6
2025
Q2 		$2.6M Sell
14,010
-10
-0.1% -$1.86K 1.89% 9
2025
Q1 		$2.94M Sell
14,020
-25
-0.2% -$4.86K 2.21% 8
2024
Q4 		$2.5M Sell
14,045
-745
-5% -$137K 1.82% 15
2024
Q3 		$2.92M Sell
14,790
-670
-4% -$125K 2.04% 12
2024
Q2 		$2.65M Sell
15,460
-432
-3% -$71.6K 2.1% 9
2024
Q1 		$2.89M Sell
15,892
-800
-5% -$138K 2.25% 8
2023
Q4 		$2.59M Buy
16,692
+350
+2% +$51K 2.03% 8
2023
Q3 		$2.44M Buy
16,342
+50
+0.3% +$7.34K 2.2% 5
2023
Q2 		$2.2M Sell
16,292
-96
-0.6% -$14.1K 2.02% 9
2023
Q1 		$2.61M Sell
16,388
-145
-0.9% -$22.2K 2.5% 4
2022
Q4 		$2.67M Sell
16,533
-60
-0.4% -$9.2K 2.56% 3
2022
Q3 		$2.23M Sell
16,593
-35
-0.2% -$5.02K 2.32% 4
2022
Q2 		$2.55M Sell
16,628
-3,410
-17% -$521K 2.53% 3
2022
Q1 		$3.25M Sell
20,038
-115
-0.6% -$16.7K 2.7% 3
2021
Q4 		$2.73M Sell
20,153
-1,474
-7% -$174K 2.32% 4
2021
Q3 		$2.33M Buy
21,627
+10
+0% +$1.14K 2.02% 6
2021
Q2 		$2.44M Buy
21,617
+48
+0.2% +$5.41K 2.12% 6
2021
Q1 		$2.33M Sell
21,569
-243
-1% -$26K 2.16% 7
2020
Q4 		$2.34M Sell
21,812
-1,106
-5% -$106K 2.54% 4
2020
Q3 		$2.01M Sell
22,918
-636
-3% -$59.9K 2.5% 4
2020
Q2 		$2.31M Buy
23,554
+1,016
+5% +$89.5K 3.12% 3
2020
Q1 		$1.72M Sell
22,538
-477
-2% -$40.6K 2.8% 4
2019
Q4 		$2.04M Sell
23,015
-29
-0.1% -$2.41K 2.27% 6
2019
Q3 		$1.75M Buy
23,044
+1,375
+6% +$94.3K 2.11% 11
2019
Q2 		$1.58M Buy
21,669
+295
+1% +$23.2K 1.86% 15
2019
Q1 		$1.72M Buy
21,374
+398
+2% +$32.6K 2.05% 11
2018
Q4 		$1.93M Sell
20,976
-140
-0.7% -$12.3K 2.61% 6
2018
Q3 		$1.85M Sell
21,116
-20
-0.1% -$1.9K 2.14% 9
2018
Q2 		$1.96M Sell
21,136
-850
-4% -$83K 1.96% 10
2018
Q1 		$2.08M Sell
21,986
-870
-4% -$95.6K 2.16% 7
2017
Q4 		$2.21M Sell
22,856
-263
-1% -$24.8K 2.16% 7
2017
Q3 		$2.05M Hold
23,119
– – 2.1% 11
2017
Q2 		$1.68M Buy
23,119
+725
+3% +$48.7K 1.82% 17
2017
Q1 		$1.46M Buy
22,394
+2,730
+14% +$172K 1.55% 25
2016
Q4 		$1.23M Buy
19,664
+8,331
+74% +$509K 1.29% 31
2016
Q3 		$715K Buy
11,333
+890
+9% +$57.6K 0.82% 45
2016
Q2 		$647K Buy
10,443
+2,900
+38% +$177K 0.77% 49
2016
Q1 		$431K Buy
7,543
+281
+4% +$15.7K 0.55% 59
2015
Q4 		$430K Buy
7,262
+225
+3% +$13K 0.54% 62
2015
Q3 		$383K Sell
7,037
-1,050
-13% -$68.3K 0.49% 66
2015
Q2 		$543K Buy
8,087
+50
+0.6% +$3.26K 0.55% 64
2015
Q1 		$470K Buy
8,037
+375
+5% +$22.7K 0.48% 69
2014
Q4 		$501K Sell
7,662
-400
-5% -$25.2K 0.5% 66
2014
Q3 		$466K Buy
+8,062
New +$448K 0.47% 72

Other funds holding ABBV

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
ATO
Alecta Tjanstepension Omsesidigt Stockholm, Sweden $23.8B AUM 34.25% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
HCM
Hamlin Capital Management New York $4.45B AUM 22.95% 1-Year Est. Return
AAMU
AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return
FWCM
Ferguson Wellman Capital Management Portland, Oregon $8.19B AUM 30.56% 1-Year Est. Return

Sippican Capital Advisors's ABBV Position: Q2 2026 in Review

Sippican Capital Advisors reduced its AbbVie (ABBV) stake by 0.58% in Q2 2026, selling an estimated $16.1K and leaving 12,947 shares worth $3.26M. The position accounts for 1.99% of the portfolio, ranked #10.

Sippican Capital Advisors first reported a position in ABBV in Q3 2014 and has held it in 48 quarters since. 1,476 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Sippican Capital Advisors held 12,947 shares of AbbVie worth $3.26M as of Q2 2026.
  • Sippican Capital Advisors sold 75 AbbVie shares in Q2 2026, an estimated $16.1K.
  • AbbVie made up 1.99% of Sippican Capital Advisors's portfolio in Q2 2026, its #10 holding.
  • Sippican Capital Advisors first reported a position in AbbVie in Q3 2014 and has held it in 48 quarters since.
  • 1,476 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Sippican Capital Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.